重要内容提示： 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 9 日 证券代码：688373 证券简称：盟科药业 公告编号：2025-053 上海盟科药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二） 股东大会召开的地点：中国（上海）自由贸易试验区爱迪生路 53 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 438 | | --- | --- | | 普通股股东人数 | 438 | | 2、出席会议的股东所持有的表决权数量 | 396,069,156 | | 普通股股东所持有表决权数量 | 396,069,156 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 60.4127 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 60.4127 | （四） 表决方式是否符合《公司法》及 ...

Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. announced the results of its 2025 restricted stock incentive plan, granting 6.36 million shares at a price of 19.77 yuan per share, aimed at enhancing employee motivation and long-term performance [1] Group 1: Incentive Plan Details - The company determined to grant 6.36 million restricted shares to 120 incentive recipients [1] - The grant price is set at 19.77 yuan per share, with the stock sourced from a directed issuance of A-share common stock [1] - The maximum validity period of the incentive plan is 48 months, with a lock-up period starting from the registration date and a minimum gap of 12 months before the first release of restrictions [1] Group 2: Financial Implications - The registration was completed on September 29, raising 125.7 million yuan for liquidity support [1] - The equity structure will see an increase of 6.36 million restricted shares [1] - The cost of the incentive plan will be accounted for in expenses, which will impact net profit in various years [1]

证券之星消息，9月30日化学制药板块较上一交易日上涨1.63%，盟科药业领涨。当日上证指数报收于 3882.78，上涨0.52%。深证成指报收于13526.51，上涨0.35%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688373 | 盟科药业 | 9.11 | 8.45% | 45.11万 | | 4.05亿 | | 002365 | 永安药业 | 18.08 | 6.92% | 40.67万 | | 7.36亿 | | 002020 | 京新药业 | 20.72 | 5.39% | 19.67万 | | 4.01亿 | | 688117 | 圣诺生物 | 40.91 | 4.58% | 5.64万 | | 2.29亿 | | 688266 | 津墙制药 | 113.01 | 4.43% | 3.36万 | | 3.73亿 | | 300723 | 一品红 | 59.43 | 4.34% | 9.31万 | | 5.47亿 | | 6885 ...

Group 1 - The brain-computer interface (BCI) industry is projected to reach USD 7.63 billion by 2029, driven by policy support and demand from medical conditions such as stroke and ALS [4] - The industry is entering a "policy-research-application" closed loop, with a clearer commercialization path [4] - Recommended companies in the BCI sector include Xiangyu Medical, Weisi Medical, Chengyitong, Mailande, Aipeng Medical, and Sanbo Neurosurgery [4] Group 2 - Mengke Pharmaceutical plans to issue 164 million shares at a price of 6.3 CNY per share, raising up to 1.033 billion CNY, which will make Haiqing Pharmaceutical the controlling shareholder [9] - The projected net profit for Mengke Pharmaceutical from 2025 to 2027 is estimated to be -241 million, -190 million, and -99 million CNY respectively, maintaining a "buy" rating [9] Group 3 - The cobalt export quota system in the Democratic Republic of the Congo (DRC) is expected to lead to a significant reduction in cobalt supply, positively impacting cobalt prices [13] - The DRC accounted for 76.3% of global cobalt production in 2024, and the supply constraints are likely to benefit companies like Huayou Cobalt and Luoyang Molybdenum [13] Group 4 - China Railway Assembly reported stable revenue growth and improved cash flow in H1 2025, with a projected net profit of 2 million, 44 million, and 68 million CNY for 2025 to 2027 [16] - The company maintains an "overweight" rating based on its financial performance [16] Group 5 - The dividend yield of Midea Group has exceeded 7%, indicating a potential bottoming out, with a projected profit of 33 billion CNY for 2025 and a 52% cash dividend rate [18] - The company maintains a "buy" rating with a target price of 54.10 CNY [18] Group 6 - The real estate market in Shanghai is experiencing increased transaction volumes due to favorable policies, with a 62.5% increase in daily average transactions post-policy implementation [29] - The top three companies in Shanghai's new home transaction value from January to August 2025 are Poly Developments, China Merchants Shekou, and China Resources Land [29] Group 7 - PetroChina has signed a USD 359 million contract with Total for the design, procurement, supply, construction, and commissioning of a project in Iraq, with projected net profits of 909 million, 1.099 billion, and 1.315 billion CNY from 2025 to 2027 [33] - The company maintains an "overweight" rating for both its A-shares and H-shares [33]

Group 1 - A total of 234 listed companies disclosed institutional research records this week, with nearly 40% of them achieving positive stock returns [1] - The stock price of Jingzhida (688627) increased by 17.68% after receiving 138 institutional inquiries, focusing on its storage testing and semiconductor testing equipment [1][2] - Xintai's stock rose by 15.81% after hosting a roadshow with 77 institutional investors, with its core revenue source being over 80% from its formulation business [2] Group 2 - Mengke Pharmaceutical announced a stock issuance plan at a price of 6.3 yuan per share, raising up to 1.033 billion yuan, with Haiqing Pharmaceutical becoming the controlling shareholder [3] - Haiqing Pharmaceutical will leverage its experience in raw material drug development to enhance Mengke's product cost efficiency and profitability [3] - Gaowei Technology received attention from over 40 institutions due to its strategic partnership with Ant Group, focusing on AI and financial technology [4][5]

Group 1: Market Overview - The macroeconomic environment remains supportive with expectations of further easing from the Federal Reserve, which has already lowered rates by 25 basis points in September, with projections for additional cuts by the end of the year [2] - A-shares are experiencing a high level of trading activity, with average daily turnover exceeding 2.45 trillion yuan in September, up from 2.31 trillion yuan in August, indicating strong market liquidity [2] - The technology sector continues to show strength, with the Wande Technology Index accounting for 40.8% of total A-share trading volume, reflecting ongoing liquidity inflows into this sector [2] Group 2: Sector Analysis - The technology sector is characterized by a clear differentiation between high and low performers, with previous leaders like optical modules and communication equipment seeing lower gains in September, while semiconductor materials and energy storage stocks have shown significant recovery [2][3] - Cyclical and dividend-paying stocks remain weak due to poor economic data, with various sectors underperforming compared to technology [3] - The current risk premium for A-shares is low, with the risk premium for the CSI 300 index at 5.19%, close to historical lows, suggesting limited downside potential [3] Group 3: Investment Strategy - The report recommends focusing on technology stocks with a strong price-performance ratio, particularly those that have lagged behind in previous rallies, to enhance potential returns [5] - There is an emphasis on upstream materials related to energy storage and semiconductor industries, such as lithium and cobalt, which are expected to benefit from ongoing demand growth in electric vehicles and semiconductor manufacturing [5] - The October stock selection includes a diverse range of sectors, highlighting companies in innovative pharmaceuticals, electronics, automotive, and communications, indicating a strategic approach to capitalize on sectoral strengths [10][11]

详式权益变动报告书 之 财务顾问核查意见 广发证券股份有限公司 关于上海盟科药业股份有限公司 2025 年 9 月 广发证券股份有限公司关于上海盟科药业股份有限公司详式权益变动报告书之财务顾问核查意见 声明 本部分所述词语或简称与本核查意见"释义"所述词语或简称具有相同含义。 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司收购 管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变 动报告书》、《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公 司收购报告书》等法律法规及规范性文件的有关规定，广发证券股份有限公司按 照行业公认的业务标准、道德规范，本着诚实信用和勤勉尽责的原则，对信息披 露义务人出具的《详式权益变动报告书》所披露的内容出具核查意见。 本财务顾问特作如下声明： 1、本财务顾问及信息披露义务人与本次权益变动行为之间不存在任何关联 关系，亦未委托或授权其他任何机构或个人提供未在本核查意见中列载的信息和 对本核查意见做任何解释或者说明。 2、本财务顾问依据的有关资料由信息披露义务人提供。信息披露义务人已 做出承诺，保证其所提供的信息和文件真实、准 ...

Core Viewpoint - The conflict between Genie Pharma, the largest shareholder of Mengke Pharmaceutical, and the founding team led by Zhengyu Yuan has intensified, particularly regarding a proposed private placement and change of control involving Haijing Pharmaceutical [1][2][3] Group 1: Shareholder Dispute - Genie Pharma holds 71.57 million shares of Mengke Pharmaceutical, accounting for 10.92% of the total share capital, and has voted against multiple proposals related to the private placement [2] - Genie Pharma has proposed to remove three directors, including founder Zhengyu Yuan, and to elect three new directors, highlighting the growing rift between the major shareholder and the founding team [2][4] - The disagreement stems from Mengke Pharmaceutical's recent announcement of a private placement to Haijing Pharmaceutical, which Genie Pharma has publicly criticized [1][3] Group 2: Private Placement Details - Mengke Pharmaceutical plans to issue 164 million shares to Haijing Pharmaceutical, raising up to 1.033 billion yuan, which would give Haijing a 20% stake and make it the controlling shareholder [1][3] - Genie Pharma has raised concerns about the financial stability of Haijing Pharmaceutical, questioning its ability to fund the private placement given its reported total assets of approximately 700 million yuan and total liabilities of about 300 million yuan [6][7] Group 3: Financial Performance and Challenges - Mengke Pharmaceutical has been facing financial difficulties, with cumulative losses of approximately 1.221 billion yuan from 2022 to mid-2025, and has not yet achieved profitability [10] - The company’s only commercial product, the antibiotic Contizolam, has limited market potential due to competition from other established products [9][10] - Mengke Pharmaceutical's cash flow has been negative for several years, with only 237 million yuan remaining as of mid-2025, raising concerns about its ability to fund ongoing research and development [10]

对于此次合作，盟科药业副总经理、首席技术官王星海表示："我们很高兴与蓬勃生物达成此次战略合 作。蓬勃生物作为国际领先的生物药开发解决方案提供者，拥有高效的创新生物药发现、开发和产业化 能力，以及完善的国际质量体系。此次与蓬勃生物合作开发若干创新型ADC药物，将最大限度地发挥 STOPIN平台技术的适用性及竞争力，并在全球范围内开发更具竞争优势的新型ADC药物。" 据了解，此次合作方蓬勃生物（ProBio），致力于为生物科技公司及制药公司提供一站式CDMO服务， 帮助全球客户加速新药研发进程，服务涵盖临床试验到商业化生产。 对于此次合作，蓬勃生物CEO国璋表示："我们非常高兴与盟科药业展开此次战略合作。盟科药业在小 分子药物研发领域积累了深厚经验，其创新的STOPIN平台为新一代ADC的安全性和疗效提升提供了突 破性的解决方案。蓬勃生物在抗体发现、CMC工艺开发及GMP生产方面拥有丰富的经验和国际领先的 技术平台。通过强强联合，我们将把双方的技术优势和资源整合，携手推进多款创新型ADC产品的开 发与全球化布局，为患者带来更安全、更有效的治疗选择，推动全球肿瘤治疗领域的发展。" （文章来源：证券时报网） 近日，上 ...

Core Viewpoint - The first major shareholder, Genie Pharma, publicly opposes the planned 1 billion yuan private placement by Mengke Pharmaceutical, which could lead to significant changes in the company's ownership structure and governance [3][4][5]. Group 1: Shareholder Opposition - Genie Pharma announced its intention to vote against the acquisition of Mengke Pharmaceutical by Nanjing Haiqing Pharmaceutical at the upcoming shareholders' meeting [3]. - Genie Pharma has also proposed the removal of three directors, criticizing the management team's capabilities and the company's ongoing losses [7][10]. - The opposition from Genie Pharma has led to a significant drop in Mengke Pharmaceutical's stock price, which fell by 10.96% to 8.61 yuan per share following the announcement [5]. Group 2: Financial and Operational Concerns - Mengke Pharmaceutical has not launched any new products since its market entry three years ago and has not achieved profitability, with continuous losses reported [6][18]. - The company aims to leverage the investment from Haiqing Pharmaceutical to break its reliance on a single product and improve its financial situation [6][15]. - Financial data shows that Mengke Pharmaceutical's net losses from 2021 to 2024 totaled over 1.3 billion yuan, with a significant decline in net assets since its IPO [20][21]. Group 3: Haiqing Pharmaceutical's Role - Haiqing Pharmaceutical plans to invest 1.033 billion yuan in Mengke Pharmaceutical, acquiring a 20% stake, which would make it the controlling shareholder [4][8]. - Concerns have been raised regarding the uncertainty of Haiqing Pharmaceutical's funding for the private placement and its potential impact on Mengke Pharmaceutical's financial stability [16]. - Haiqing Pharmaceutical's financial health is questioned, with total assets of approximately 700 million yuan and total liabilities of about 300 million yuan as of mid-2025 [16]. Group 4: Management and Strategic Issues - The management team of Mengke Pharmaceutical has faced criticism for its inability to generate profits and for the company's deteriorating financial condition [17][19]. - The company has been heavily reliant on its sole product, Kangtaizuoan, which has seen increasing sales but is insufficient to cover overall operational costs [22][23]. - Mengke Pharmaceutical's high sales expenses, which reached 110 million yuan in 2024, have raised concerns about the sustainability of its business model [23][25].